KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
- Kindred Biosciences Announces Second Quarter 2017 Financial ResultsAugust 7, 2017 - 4:02 pm
- Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners MeetingAugust 4, 2017 - 9:04 am
- Kindred Biosciences to Announce Second Quarter 2017 Financial ResultsJuly 24, 2017 - 9:04 am